Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: J Am Acad Dermatol. 2020 May 13;83(5):1341–1348. doi: 10.1016/j.jaad.2020.05.007

Fig 4.

Fig 4.

A, C, E, and G, Ultrasonographic changes at baseline and (B, D, F, H) after 12 weeks of treatment with brodalumab. Dermal Doppler ultrasonography intensity in lesional dermal tissues at (A) baseline (blue arrows) is significantly attenuated at (B) week 12 (blue arrows) of therapy. The diameter of draining tunnels (yellow arrows) and surrounding edema (yellow asterisk) at (C) baseline is also reduced at (D) week 12. Similarly, Doppler intensity (red arrows) surrounding (E) epithelialized dermal tunnels (F) reduces at week 12 compared with baseline. The diameter and echogenicity of dermal tunnels (green arrows) is also (H) attenuated at week 12 compared with (G) baseline.